Tags: CDC, Coronavirus, COVID, Covid19, Health, vaccine
Please scroll below for the latest COVID-19 vaccine news (updated weekly). NOTE: TBG’s COVID-19 Team, provides a comprehensive and integrated package of COVID-19 Solutions covering Public Health, Testing and Tracing, Crisis Management, Research and Data Management, and PPE Supplies. To get access to the Team, just send an email.
March 2, 2021: Drugmaker Merck & Co. announced that it will help produce rival Johnson & Johnson’s newly approved coronavirus vaccine in an effort to expand supply more quickly, a Biden administration official confirmed Tuesday.
The announcement comes as the White House looks to speed the production of the single-dose vaccine. Officials have said J&J faced unexpected production issues with its vaccine and produced only 3.9 million doses ahead of its receiving emergency use authorization on Saturday. The company says it is on pace to deliver 100 million doses by the end of June.
Facing questions about the company’s slipping delivery schedule, J&J Vice President Richard Nettles told lawmakers on Capitol Hill last week that the company had faced “significant challenges” because of its “highly complex” manufacturing process.
The assistance from Merck was expected to help J&J meet its production commitments and expand supply even further, but the administration did not immediately provide specifics.
- The FDA has approved J&J’s Covid-19 vaccine for emergency use, giving the U.S. a third tool to fight the pandemic.
- Unlike Pfizer’s and Moderna’s vaccines, J&J’s one-dose regimen eliminates the need for patients to return for a second dose and it can be stored at refrigerator temperatures for months.
- The federal government plans to distribute nearly 4 million doses of J&J’s vaccine to states, pharmacies and community health centers across the nation next week.
he Food and Drug Administration has approved Johnson & Johnson’s Covid-19 vaccine for emergency use, giving the United States a third tool to fight the pandemic as highly contagious variants start to take root across the country.
The FDA’s emergency use authorization Saturday kickstarts the federal government’s plan to distribute nearly 4 million doses of J&J’s vaccine to states, pharmacies and community health centers across the nation next week. Unlike Pfizer’s and Moderna’s vaccines, J&J’s one-dose regimen eliminates the need for patients to return for a second dose and it can be stored at refrigerator temperatures for months.
J&J’s vaccine “makes it operationally easier in lots of contexts,” Dr. Nancy Messonnier, director of the CDC’s National Center for Immunization and Respiratory Diseases, told the Journal of the American Medical Association during a Q&A event on Friday. “I expect lots of considerations state health departments are having around these vaccines is more about the ease of use of the J&J vaccine and how it might be better suited for some populations.”
Initially, doses would be limited, J&J has said. The company expects to deliver 20 million doses by the end of March, J&J’s vice president of U.S. medical affairs, Dr. Richard Nettles, told House lawmakers on Tuesday. J&J has a deal with the U.S. government to supply 100 million doses of its vaccine by the end of June, and U.S. officials say they are working with the company to ramp up supply as quickly as possible.
The coronavirus vaccine made by Johnson & Johnson provides strong protection against severe disease and death from Covid-19, and may reduce the spread of the virus by vaccinated people, according to new analyses released Wednesday by the company and the Food and Drug Administration.
The reports provided confirmation of the initial results announced by Johnson & Johnson late last month, indicating that the United States is likely to soon have access to a third coronavirus vaccine developed in under a year. The F.D.A. could authorize the vaccine as early as Saturday, depending on a vote by its vaccine advisory panel on Friday, and distribution could begin within days.
If cleared, the vaccine would reach a number of firsts for the U.S. pandemic. Unlike the authorized vaccines made by Pfizer-BioNTech and Moderna, which require two doses, Johnson & Johnson’s is just a single shot, allowing the number of fully vaccinated Americans to rapidly increase once it is deployed. More than 44 million Americans have received at least one dose of the Moderna and Pfizer vaccines, but only around 20 million have received a second dose.
In an analysis released Wednesday, the US Food and Drug Administration said the Johnson & Johnson Covid-19 vaccine has met the requirements for emergency use authorization — another step toward the authorization of a third shot for the United States.
The Biden administration announced Tuesday that it is further increasing the weekly vaccine shipments the federal government sends to states.
The White House’s COVID-19 response team announced that states will now receive 14.5 million doses starting next week, a jump from 13.5 million.
The team tweeted that the figure is “an increase of almost 70% since we took office just over a month ago.”
Covid-19 vaccine distribution rates in the U.S. are likely to accelerate in the coming months to potentially twice the amount now being administered, as vaccine manufacturers project substantial boosts in production and the White House increases the number of doses it sends out to states.
Vaccine manufacturers Pfizer and Moderna testified to Congress Tuesday they’re both on track to deliver 300 million doses each by the end of July—which would vaccinate 300 million people, since both shots require two doses—and manufacturing improvements will let them increase the number of vaccines they’re able to ship out even sooner.
Pfizer will be able to ship more than 13 million doses by mid-March, Chief Business Officer John Young testified Tuesday—up from four to five million per week at the start of February—providing 120 million doses in total by the end of March and an additional 80 million doses by the end of May.
Moderna President Stephen Hoge told lawmakers the company will have delivered 100 million doses of the vaccine to the U.S. government by the end of March and will move up its schedule to send out a second 100 million by the end of May; more than 40 million monthly doses will be sent out by April, double the company’s current rate.
If the Johnson & Johnson vaccine is approved after the Food and Drug Administration discusses it later this week, the company is on track to provide enough of the single-shot vaccine to cover 20 million Americans by the end of March and 100 million in the first half of 2021, Dr. Richard Nettles, Vice President of U.S. Medical Affairs at Johnson & Johnson’s Janssen Infectious Diseases and Vaccines, testified.
The federal government is steadily increasing the number of vaccines it distributes to states, announcing Tuesday states will receive 14.5 million doses this week—up from 13.5 million last week and 8.6 million in Biden’s first week in office, an increase of nearly 70%.
Bloomberg projects there will be enough vaccine supply to vaccinate 130 million Americans by the end of March based on the three companies’ projections, and approximately 200 million people by April 30.
Despite the 95 percent effectiveness at preventing coronavirus infection after two doses of its vaccine, Pfizer is now seeing what a third dose might do.
The company announced Thursday that a booster dose is being studied among people who received their first doses of the vaccine more than six months ago.
In an interview with NBC News’ Lester Holt, Pfizer CEO Albert Bourla said the hope is that a third dose will boost the immune response even higher, offering better protection against variants.
“We believe that the third dose,” Bourla said, “will raise the antibody response 10- to 20- fold.”
The new study will monitor the safety and efficacy of a third dose in two age groups: those 18 to 55 and those 65 to 85. The participants come from a group of people who were among the first to receive the Pfizer-BioNTech vaccine: people who volunteered for Pfizer’s initial Phase 1/2 clinical trial, which began in May.
During that trial, participants received two doses of the vaccine three weeks apart. The same dose interval is what’s currently recommended.
The third shot will be exactly the same as what participants got a year ago.
The first shipment of Covid-19 vaccines delivered through the World Health Organization’s COVAX program arrived in Ghana on Wednesday, a hopeful turning point for developing countries that risk being left behind in the global race for vaccinations against a virus that has killed nearly 2.5 million people worldwide.
The flight brought 600,000 doses of the AstraZeneca vaccine, one considered far easier to distribute to developing nations since it doesn’t require extremely cold storage temperatures like the Pfizer–GenTech and Moderna vaccines.
The vaccines delivered Wednesday will be prioritized for front-line medical workers, people over 60, and those with preexisting health conditions, according to Ghana’s Information Ministry.
“Today marks the historic moment for which we have been planning and working so hard,” UNICEF Executive Director Henrietta Fore said in a joint statement by her agency and the WHO Ghana.
NOTE: TBG’s COVID-19 Team, provides a comprehensive and integrated package of COVID-19 Solutions covering Public Health, Testing and Tracing, Crisis Management, Research and Data Management, and PPE Supplies. To get access to the Team, just send an email.
#covid #covid19 #coronavirus #vaccine #covidvaccine #novavax #moderna #pfizer #vaccinetrial #vaccinedose #dose #southafrica #africa #drug #disease #health #publichealth #CDC
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- November 2019
- October 2019
- July 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- December 2014
- November 2014
- October 2014
- August 2014
- July 2014
- June 2014
- December 2013
- November 2013
- September 2013